#USA #Orlando #RNA Therapeutics #Avidity Biosciences #Duchenne Muscular Dystrophy

Avidity Biosciences to Showcase Research at 2026 MDA Conference

Avidity Biosciences, Inc. is poised to make a significant impact at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. Taking place from March 8 to 11, 2026, in Orlando, Florida, this event will serve as a platform for discussions and presentations on state-of-the-art research focused on muscular dystrophies. The company, publicly traded on Nasdaq under the ticker RNA, specializes in developing RNA therapeutics designed to improve the lives of individuals affected by various neuromuscular disorders.

Highlighted Presentations

Avidity will introduce a total of seven presentations, comprised of one oral and six poster presentations. These sessions are expected to showcase the latest advancements in the field of RNA therapeutic interventions, particularly how they relate to Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).

The oral presentation, titled "Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44", will be made by Dr. Craig McDonald. He serves as the Professor and Chair of the Departments of Physical Medicine and Rehabilitation at the University of California, Davis. His research will present compelling data from Avidity’s Phase 1/2 EXPLORE44 program, demonstrating notable progress in patients with DMD mutations that are amenable to exon 44 skipping.

Poster Presentations

In addition to the primary oral presentation, Avidity will share findings through several posters covering a range of topics, including the patient experience in Myotonic Dystrophy and treatment journey insights. The poster sessions are as follows:

• - #138 Patient journey insights among individuals with Myotonic Dystrophy Type 1 (DM1) (March 9, 2026)
• - #129 Participant experiences with DM1 and Treatment with Del-desiran (March 9, 2026)
• - #313 Examination of DUX4 effects in FSHD cell line models (March 10, 2026)
• - #303 The humanistic burden related to Facioscapulohumeral Muscular Dystrophy (March 10, 2026)
• - #165 Overview of a Phase 3 study design for delpacibart zotadirsen in treating DMD44 (March 9, 2026)
• - #53 Impact of delpacibart zotadirsen on inflammatory and fibrotic disease signatures in DMD44 muscle (March 8, 2026)

All presentations and posters will soon be accessible on the publications page of Avidity’s website after the event concludes.

Industry Forum and Networking Opportunities

In addition to the presentations, Avidity is sponsoring an industry forum lunch on March 10, 2026. The event will be held from 12:00 PM to 1:30 PM ET in room Key West ABCD at the Hilton Orlando. This forum, titled "Biomarker Advancements in Rare Neuromuscular Disease: Insights from DMD and FSHD," will feature expert speakers including Dr. Aravindhan Veerapandiyan from Arkansas Children’s Hospital and Dr. Stephen Tapscott from Fred Hutchinson Cancer Center. These presentations aim to foster discussions on the critical advancements related to biomarker identification in rare diseases.

Commitment to Innovation

Avidity Biosciences stands at the forefront of RNA therapeutics with its pioneering approach to Antibody Oligonucleotide Conjugates (AOCs™). This unique technology aims to combine the specificity of monoclonal antibodies with the precise targeting capabilities of oligonucleotides to address previously untreatable conditions. Their work is not limited to neuromuscular diseases; efforts are underway in the fields of cardiology and immunology, expanding their innovative pipeline through strategic partnerships.

As they prepare for the MDA Conference, Avidity is not only focused on presenting their findings but also on engaging with the broader community to drive forward the research landscape in neuromuscular disorders. By showcasing their latest developments, they hope to inspire collaboration and enhance the understanding of treatments available for individuals impacted by these challenging conditions.